Clinical Trial Update: Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating maintenance Erbitux after irinotecan-based frontline therapy in patients with wild-type RAS metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: UNICANCER | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED